Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1993 1
1997 1
2001 2
2002 1
2005 2
2006 1
2019 1
2020 1
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Neonatal transport.
Donn SM, Faix RG, Gates MR. Donn SM, et al. Among authors: gates mr. Curr Probl Pediatr. 1985 Apr;15(4):1-65. doi: 10.1016/0045-9380(85)90051-9. Curr Probl Pediatr. 1985. PMID: 3888538 Review. No abstract available.
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.
Jhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, Sohn J, Neilan TG, Villanueva-Vázquez R, Kabos P, García-Estévez L, López-Miranda E, Pérez-Fidalgo JA, Pérez-García JM, Yu J, Fredrickson J, Moore HM, Chang CW, Bond JW, Eng-Wong J, Gates MR, Lim E. Jhaveri KL, et al. Among authors: gates mr. Clin Cancer Res. 2024 Feb 16;30(4):754-766. doi: 10.1158/1078-0432.CCR-23-1796. Clin Cancer Res. 2024. PMID: 37921755 Free PMC article. Clinical Trial.
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
Liang J, Ingalla ER, Yao X, Wang BE, Tai L, Giltnane J, Liang Y, Daemen A, Moore HM, Aimi J, Chang CW, Gates MR, Eng-Wong J, Tam L, Bacarro N, Roose-Girma M, Bellet M, Hafner M, Metcalfe C. Liang J, et al. Among authors: gates mr. Sci Transl Med. 2022 Sep 21;14(663):eabo5959. doi: 10.1126/scitranslmed.abo5959. Epub 2022 Sep 21. Sci Transl Med. 2022. PMID: 36130016
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Shapiro GI, LoRusso P, Kwak E, Pandya S, Rudin CM, Kurkjian C, Cleary JM, Pilat MJ, Jones S, de Crespigny A, Fredrickson J, Musib L, Yan Y, Wongchenko M, Hsieh HJ, Gates MR, Chan IT, Bendell J. Shapiro GI, et al. Among authors: gates mr. Invest New Drugs. 2020 Apr;38(2):419-432. doi: 10.1007/s10637-019-00776-6. Epub 2019 Apr 24. Invest New Drugs. 2020. PMID: 31020608 Clinical Trial.
14 results